This phase II trial investigates the utility of fludeoxyglucose F-18 (FDG) positron emission tomography/computed tomography (PET/CT) as a predictor of response to neoadjuvant chemotherapy in patients with HER2-Positive Breast Cancer. The study enrolled 235 participants diagnosed with Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, HER2-Positive Breast Carcinoma, and Invasive Breast Carcinoma.
Patient Characteristics and Imaging Protocol
Participants received standard of care chemotherapy and underwent FDG-PET/CT imaging, utilizing FDG as a radioactive tracer to identify areas of active cancer. Computed tomography was also performed to create detailed computerized images of the body’s interior. Patients received FDG intravenously, underwent PET/CT, received standard of care chemotherapy, and ultimately underwent standard of care surgery as part of the study’s outline.
Study Objectives
The study’s primary objective was to estimate the negative predictive value (NPV) of neoadjuvant interim (ni)FDG-PET/CT for pathologic complete response (pCR), using deltaSULmaxD15 corrected for lean body mass day 15, completed through central review, of the primary breast cancer at a threshold of 40%. Secondary objectives included estimating the sensitivity, specificity, and positive predictive value (PPV) of niFDG-PET/CT for pCR, as well as evaluating the performance of niFDG-PET/CT as a predictor of 3-year event-free survival (EFS) from time of study registration. Exploratory objectives included estimating the NPV of niFDG-PET/CT for pCR using deltaSULmaxD15 at alternative thresholds ranging from 30% to 60%, and comparing deltaSULmaxD15 using automated image analysis of FDG-PET/CT by AutoPERCIST (trademark) to standard PET analysis software.